Bone marrow‐derived mononuclear cell therapy for nonischaemic dilated cardiomyopathy—A meta‐analysis

Bone marrow‐derived mononuclear cell therapy for nonischaemic dilated cardiomyopathy—A... INTRODUCTIONNonischaemic dilated cardiomyopathy (DCM) is defined as left ventricular (LV) dilation and systolic dysfunction in the absence of coronary artery disease or abnormal loading conditions proportionate to the degree of LV impairment. As one of the leading causes of heart failure (HF), DCM (either ischaemic or nonischaemic) is the most frequent indication for ventricular assist device and/or cardiac transplantation. The major determinant of adverse outcomes in DCM is the extent of LV dilation and contractile impairment, while the key therapeutic goal was reversal of these abnormalities and LV reverse remodelling.Improving outcome of DCM remains a difficult goal to achieve. The treatment of HF due to DCM, other than standard pharmaceuticals and heart transplantation, is limited. To improve the prognosis and quality of life for HF patients, either due to ischaemic or nonischaemic causes, therapeutic strategies should alter the remodelling process, regenerate cardiomyocytes and repair myocardium. Heart has no intrinsic muscular regeneration capacity. To restore cardiac function and regenerate cardiomyocytes, regenerative medicine techniques are being increasingly investigated. As a potential therapeutic approach, cell‐based therapies have rapidly emerged. Different cell strains used include bone marrow mononuclear cells (BMMCs), G‐CSF‐stimulated autologous CD34+ peripheral blood stem cells (PBSC), embryonic stem cells (ESCs), skeletal http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png European Journal of Clinical Investigation Wiley

Bone marrow‐derived mononuclear cell therapy for nonischaemic dilated cardiomyopathy—A meta‐analysis

Loading next page...
 
/lp/wiley/bone-marrow-derived-mononuclear-cell-therapy-for-nonischaemic-dilated-AUv0ODt3cA
Publisher
Wiley Subscription Services, Inc., A Wiley Company
Copyright
Copyright © 2018 Stichting European Society for Clinical Investigation Journal Foundation. Published by John Wiley & Sons Ltd
ISSN
0014-2972
eISSN
1365-2362
D.O.I.
10.1111/eci.12894
Publisher site
See Article on Publisher Site

Abstract

INTRODUCTIONNonischaemic dilated cardiomyopathy (DCM) is defined as left ventricular (LV) dilation and systolic dysfunction in the absence of coronary artery disease or abnormal loading conditions proportionate to the degree of LV impairment. As one of the leading causes of heart failure (HF), DCM (either ischaemic or nonischaemic) is the most frequent indication for ventricular assist device and/or cardiac transplantation. The major determinant of adverse outcomes in DCM is the extent of LV dilation and contractile impairment, while the key therapeutic goal was reversal of these abnormalities and LV reverse remodelling.Improving outcome of DCM remains a difficult goal to achieve. The treatment of HF due to DCM, other than standard pharmaceuticals and heart transplantation, is limited. To improve the prognosis and quality of life for HF patients, either due to ischaemic or nonischaemic causes, therapeutic strategies should alter the remodelling process, regenerate cardiomyocytes and repair myocardium. Heart has no intrinsic muscular regeneration capacity. To restore cardiac function and regenerate cardiomyocytes, regenerative medicine techniques are being increasingly investigated. As a potential therapeutic approach, cell‐based therapies have rapidly emerged. Different cell strains used include bone marrow mononuclear cells (BMMCs), G‐CSF‐stimulated autologous CD34+ peripheral blood stem cells (PBSC), embryonic stem cells (ESCs), skeletal

Journal

European Journal of Clinical InvestigationWiley

Published: Jan 1, 2018

Keywords: ; ; ;

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off